Proteomics Analysis of Polyphyllin D-Treated Triple-Negative Breast Cancer Cells Reveal the Anticancer Mechanisms of Polyphyllin D
-
Published:2023-08-25
Issue:
Volume:
Page:
-
ISSN:0273-2289
-
Container-title:Applied Biochemistry and Biotechnology
-
language:en
-
Short-container-title:Appl Biochem Biotechnol
Author:
Wei Chuanchao,Mao Anwei,Liu Yongzhi,Zhang Qing,Pan Gaofeng,Liu Weiyan,Liu Jiazhe
Abstract
AbstractPolyphyllin D (PD), one of the important steroid saponins in traditional medicinal herb Paris polyphylla, has been demonstrated to have anticancer activity both in vitro and in vivo. However, the mechanisms through which PD exerts its anticancer effects in triple-negative breast cancer (TNBC) remain unclear. Our study was presented to evaluate the anticancer effect and the potential mechanisms of PD in two TNBC cell lines, BT-549 and MDA-MB-231. Through comprehensively comparing the liquid chromatography-tandem mass spectrometry (LC–MS/MS) data of PD-treated and untreated BT-549 and MDA-MB-231 cells, we found that PD could induce apoptosis of TNBC cells by activating oxidative phosphorylation pathway in BT-549 cells, as well as inhibiting spliceosome function alteration in MDA-MB-231 cells. These results suggested that the mechanisms underlying the pro-apoptotic effect of PD on TNBC may be cell type-specificity-dependent. Moreover, we found that nodal modulator 2/3 (NOMO2/3) were downregulated both in PD-treated BT-549 and MDA-MB-231 cells, suggesting that NOMO2/3 may be the potential target of PD. Verification experiments revealed that PD deceased NOMO2/3 expression at protein level, rather than mRNA level. Whether NOMO2/3 are the upstream modulators of oxidative phosphorylation pathway and spliceosome needs further validation. In conclusion, a comprehensive proteomics study was performed on PD-treated or untreated TNBC cells, revealing the anticancer mechanisms of PD.
Funder
Shanghai Science International Cooperation Project
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,General Medicine,Bioengineering,Biotechnology
Reference43 articles.
1. Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7–30. 2. Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019). Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment. Cancer Discovery, 9, 176–198. 3. Asong, G. M., Voshavar, C., Amissah, F., Bricker, B., Lamango, N. S. and Ablordeppey, S. Y. (2022). An evaluation of the anticancer properties of SYA014, a homopiperazine-oxime analog of haloperidol in triple negative breast cancer cells. Cancers (Basel), 14. 4. Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021). Breast cancer. Lancet, 397, 1750–1769. 5. Liao, M., Zhang, J., Wang, G., Wang, L., Liu, J., Ouyang, L., & Liu, B. (2021). Small-molecule drug discovery in triple negative breast cancer: Current situation and future directions. Journal of Medicinal Chemistry, 64, 2382–2418.
|
|